TAMPA, Fla. and SAN DIEGO, June 15, 2016 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that BUYINS.NET, http://www.buyins.net/, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on HedgePath Pharmaceuticals (OTC: HPPI) after releasing the latest short sale data through June 10, 2016. The total aggregate number of shares shorted since August 2009 is approximately 4.6 million shares. Approximately 28.39% of total trading volume is short selling. The SqueezeTrigger price for all HPPI shares shorted is $0.298. A short squeeze is expected to begin when shares of HPPI cross above the $0.298 SqueezeTrigger Price.
Click here to view Report: http://www.buyins.com/reports/hppi6-12-16.pdf
Click here for SqueezeTrigger: http://www.buyins.com/images2/hppistr6-12-16.jpg
Click here for Friction Factor: http://www.buyins.com/images2/hppiff6-12-16.jpg
Click here for detailed explanation: http://www.buyins.com/brochure.pdf
Friction Factor calculates if a fair market is being made in the shares of HPPI. 57% of the previous 16 trading days have been positive or bullish-biased and 43% have been negative or bearish-biased.
Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The Commission has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies for investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.
BUYINS.NET monitors HPPI market-makers daily for compliance with Fair Market-Making Requirements.
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations.
About HedgePath Pharmaceuticals
HedgePath Pharmaceuticals, Inc. (HPPI) is a clinical stage biopharmaceutical company that is seeking to repurpose the FDA approved antifungal pharmaceutical itraconazole as a potential treatment for cancer. HPPI is the exclusive U.S. licensee of a patented formulation of itraconazole, called SUBA-Itraconazole, which clinical studies have shown to have greater bioavailability than generic itraconazole.
The Hedgehog signaling pathway is a major regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity and cell proliferation. Based on published research, HPPI believes that inhibiting the Hedgehog pathway could delay or possibly prevent the development of certain cancers in humans. Leveraging research undertaken by key investigators in the field, HPPI plans to explore the effectiveness of SUBA-Itraconazole as an anti-cancer agent and to pursue its potential commercialization. HPPI has offices in Tampa, Florida and San Diego, California. For more information, please visit www.hedgepathpharma.com .
Cautionary Note Regarding Forward Looking Statements
This press release and any statements of representatives and partners of HedgePath Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the actual timing for, or actual results of, the Company's clinical trial described herein or the FDA's review of such results) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
BUYINS.NET is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. The Company has paid $1,167 per month for six months of data provided in this report and subsequent reports. HPPI has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Nicholas J. Virca, President and CEO
Investor Relations Contact:
Garry Hasara, CFO & Treasurer
Logo - http://photos.prnewswire.com/prnh/20150928/271412LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/buyinsnet-issues-hedgepath-pharmaceuticals-hppi-squeezetrigger-report-300284810.html
SOURCE HedgePath Pharmaceuticals, Inc.